Phase II evaluation of dibromodulcitol and actinomycin D, hydroxyurea, and cyclophosphamide in previously untreated patients with malignant melanomaQuantitative Health Sciences Publications and Presentations
UMMS AffiliationDepartment of Quantitative Health Sciences
Medical Subject HeadingsAdolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; effects; Cyclophosphamide; Dactinomycin; Drug Evaluation; Female; Humans; Hydroxyurea; Male; Melanoma; Middle Aged; Mitolactol; Semustine
AbstractIn this Eastern Cooperative Oncology Group (ECOG) phase II study, dibromodulcitol (DBD) and a combination of actinomycin D, hydroxyurea, and cyclophosphamide (AHC) were compared with methyl-CCNU, the current ECOG standard, in patients who had received no prior chemotherapy for disseminated malignant melanoma. The response rates were 6% (3/50) for AHC, 9% (3/34) for DBD, and 14% (7/49) for methyl-CCNU. Median survival times were 4, 5, and 6 months, respectively. Neither regimen appears to offer any advantage over methyl-CCNU as front-line therapy for patients with disseminated melanoma.
Rights and PermissionsCitation: Invest New Drugs. 1987;5(3):293-7. Link to article on publisher's site
Related ResourcesLink to Article in PubMed
Citation InformationDavid A. Amato, Howard Bruckner, DuPont Guerry, Arlene S. Ash, et al.. "Phase II evaluation of dibromodulcitol and actinomycin D, hydroxyurea, and cyclophosphamide in previously untreated patients with malignant melanoma" Vol. 5 Iss. 3 (1987) ISSN: 0167-6997 (Linking)
Available at: http://works.bepress.com/arlene_ash/49/